Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

FISH analysis for TET2 deletion in a cohort of 362 Brazilian myeloid malignancies: correlation with karyotype abnormalities.

de Oliveira FM, Miguel CE, Lucena-Araujo AR, de Lima AS, Falcão RP, Rego EM.

Med Oncol. 2013 Mar;30(1):483. doi: 10.1007/s12032-013-0483-1. Epub 2013 Feb 7.

PMID:
23389918
2.

Detection of TET2 abnormalities by fluorescence in situ hybridization in 41 patients with myelodysplastic syndrome.

Dambruoso I, Boni M, Rossi M, Zappasodi P, Calvello C, Zappatore R, Cavigliano PM, Giardini I, Rocca B, Caresana M, Astori C, Cazzola M, Castagnola C, Bernasconi P.

Cancer Genet. 2012 Jun;205(6):285-94. doi: 10.1016/j.cancergen.2012.03.004.

PMID:
22749034
3.

FISH analysis reveals frequent co-occurrence of 4q24/TET2 and 5q and/or 7q deletions.

La Starza R, Crescenzi B, Nofrini V, Barba G, Matteucci C, Brandimarte L, Pierini V, Testoni N, Musto P, Paolini S, Gianfelici V, Storlazzi CT, Pierini A, Berchicci L, Gorello P, Mecucci C.

Leuk Res. 2012 Jan;36(1):37-41. doi: 10.1016/j.leukres.2011.08.004. Epub 2011 Sep 13.

PMID:
21920603
4.

Mutation in TET2 in myeloid cancers.

Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, Lécluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Viguié F, Fontenay M, Vainchenker W, Bernard OA.

N Engl J Med. 2009 May 28;360(22):2289-301. doi: 10.1056/NEJMoa0810069.

5.

Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes.

Abáigar M, Robledo C, Benito R, Ramos F, Díez-Campelo M, Hermosín L, Sánchez-Del-Real J, Alonso JM, Cuello R, Megido M, Rodríguez JN, Martín-Núñez G, Aguilar C, Vargas M, Martín AA, García JL, Kohlmann A, Del Cañizo MC, Hernández-Rivas JM.

PLoS One. 2016 Oct 14;11(10):e0164370. doi: 10.1371/journal.pone.0164370. eCollection 2016.

6.

TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele.

Bacher U, Weissmann S, Kohlmann A, Schindela S, Alpermann T, Schnittger S, Kern W, Haferlach T, Haferlach C.

Br J Haematol. 2012 Jan;156(1):67-75. doi: 10.1111/j.1365-2141.2011.08911.x. Epub 2011 Oct 24.

PMID:
22017486
7.

Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.

Sugimoto Y, Sekeres MA, Makishima H, Traina F, Visconte V, Jankowska A, Jerez A, Szpurka H, O'Keefe CL, Guinta K, Afable M, Tiu R, McGraw KL, List AF, Maciejewski J.

J Hematol Oncol. 2012 Mar 5;5:4. doi: 10.1186/1756-8722-5-4.

8.

ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.

Haferlach C, Bacher U, Schnittger S, Alpermann T, Zenger M, Kern W, Haferlach T.

Genes Chromosomes Cancer. 2012 Apr;51(4):328-37. doi: 10.1002/gcc.21918. Epub 2011 Dec 8.

PMID:
22162288
9.

Evaluation of TET2 deletions in myeloid disorders: a fluorescence in situ hybridization analysis of 109 cases.

Klaus M, Psaraki A, Mastrodemou S, Pyrovolaki K, Mavroudi I, Kalpadakis C, Papadaki HA.

Leuk Res. 2011 Mar;35(3):413-5. doi: 10.1016/j.leukres.2010.10.023. Epub 2010 Nov 18.

PMID:
21087791
10.

Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.

Haferlach C, Bacher U, Grossmann V, Schindela S, Zenger M, Kohlmann A, Kern W, Haferlach T, Schnittger S.

Genes Chromosomes Cancer. 2012 Dec;51(12):1079-85. doi: 10.1002/gcc.21992. Epub 2012 Aug 8.

PMID:
22887804
12.

Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.

Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J, O'Keefe CL, Ganetzky R, McDevitt MA, Maciejewski JP.

Blood. 2009 Jun 18;113(25):6403-10. doi: 10.1182/blood-2009-02-205690. Epub 2009 Apr 16.

13.

Myeloid malignancies with acquired trisomy 21 as the sole cytogenetic change are clinically highly variable and display a heterogeneous pattern of copy number alterations and mutations.

Larsson N, Lilljebjörn H, Lassen C, Johansson B, Fioretos T.

Eur J Haematol. 2012 Feb;88(2):136-43. doi: 10.1111/j.1600-0609.2011.01710.x. Epub 2011 Nov 17.

PMID:
21933280
14.

Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.

Volkert S, Kohlmann A, Schnittger S, Kern W, Haferlach T, Haferlach C.

Genes Chromosomes Cancer. 2014 May;53(5):402-10. doi: 10.1002/gcc.22151. Epub 2014 Feb 3.

PMID:
24493299
15.

Landscape of TET2 mutations in acute myeloid leukemia.

Weissmann S, Alpermann T, Grossmann V, Kowarsch A, Nadarajah N, Eder C, Dicker F, Fasan A, Haferlach C, Haferlach T, Kern W, Schnittger S, Kohlmann A.

Leukemia. 2012 May;26(5):934-42. doi: 10.1038/leu.2011.326. Epub 2011 Nov 25.

PMID:
22116554
16.

Comprehensive array CGH of normal karyotype myelodysplastic syndromes reveals hidden recurrent and individual genomic copy number alterations with prognostic relevance.

Thiel A, Beier M, Ingenhag D, Servan K, Hein M, Moeller V, Betz B, Hildebrandt B, Evers C, Germing U, Royer-Pokora B.

Leukemia. 2011 Mar;25(3):387-99. doi: 10.1038/leu.2010.293. Epub 2011 Jan 28.

PMID:
21274003
17.

Prognostic significance of del(20q) in patients with hematological malignancies.

Brezinová J, Zemanová Z, Ransdorfová S, Sindelárová L, Sisková M, Neuwirtová R, Cermák J, Michalová K.

Cancer Genet Cytogenet. 2005 Jul 15;160(2):188-92.

PMID:
15993278
18.

Comparison of I-FISH and G-banding for the detection of chromosomal abnormalities during the evolution of myelodysplastic syndrome.

Pinheiro RF, Chauffaille ML.

Braz J Med Biol Res. 2009 Nov;42(11):1110-2. doi: 10.1590/S0100-879X2009001100018.

19.

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.

Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, Preudhomme C, Adès L, Fenaux P, Fontenay M; Groupe Francophone des Myelodysplasies (GFM).

Leukemia. 2011 Jul;25(7):1147-52. doi: 10.1038/leu.2011.71. Epub 2011 Apr 15.

PMID:
21494260
20.

Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes.

Scopim-Ribeiro R, Machado-Neto JA, Campos Pde M, Silva CA, Favaro P, Lorand-Metze I, Costa FF, Saad ST, Traina F.

Eur J Haematol. 2015 May;94(5):413-8. doi: 10.1111/ejh.12445. Epub 2014 Oct 1.

PMID:
25200248

Supplemental Content

Support Center